Frontiers in Immunology (Sep 2024)
Plasma adenosine deaminase-1 and -2 activities are lower at birth in Papua New Guinea than in The Gambia but converge over the first weeks of life
- Thomas S. Kouyate,
- Athena N. Nguyen,
- Alec L. Plotkin,
- Rebeca Ford,
- Olubukola T. Idoko,
- Olubukola T. Idoko,
- Oludare A. Odumade,
- Oludare A. Odumade,
- Oludare A. Odumade,
- Geraldine Masiria,
- Joe Jude,
- Joann Diray-Arce,
- Joann Diray-Arce,
- Kerry McEnaney,
- Al Ozonoff,
- Al Ozonoff,
- Al Ozonoff,
- Hanno Steen,
- Hanno Steen,
- Hanno Steen,
- Tobias R. Kollmann,
- Peter C. Richmond,
- Peter C. Richmond,
- Anita H. J. van den Biggelaar,
- Beate Kampmann,
- Beate Kampmann,
- William Pomat,
- Ofer Levy,
- Ofer Levy,
- Ofer Levy,
- Kinga K. Smolen,
- Kinga K. Smolen
Affiliations
- Thomas S. Kouyate
- Precision Vaccines Program, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United States
- Athena N. Nguyen
- Precision Vaccines Program, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United States
- Alec L. Plotkin
- Precision Vaccines Program, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United States
- Rebeca Ford
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- Olubukola T. Idoko
- Vaccines & Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, Gambia
- Olubukola T. Idoko
- The Vaccine Centre, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
- Oludare A. Odumade
- Precision Vaccines Program, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United States
- Oludare A. Odumade
- Harvard Medical School, Boston, MA, United States
- Oludare A. Odumade
- Division of Medicine Critical Care, Boston Children’s Hospital, Boston, MA, United States
- Geraldine Masiria
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- Joe Jude
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- Joann Diray-Arce
- Precision Vaccines Program, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United States
- Joann Diray-Arce
- Harvard Medical School, Boston, MA, United States
- Kerry McEnaney
- Precision Vaccines Program, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United States
- Al Ozonoff
- Precision Vaccines Program, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United States
- Al Ozonoff
- Harvard Medical School, Boston, MA, United States
- Al Ozonoff
- Broad Institute of Massachusetts Institute of Technology & Harvard, Cambridge, MA, United States
- Hanno Steen
- Precision Vaccines Program, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United States
- Hanno Steen
- Harvard Medical School, Boston, MA, United States
- Hanno Steen
- Department of Pathology, Boston Children’s Hospital, Boston, MA, United States
- Tobias R. Kollmann
- Telethon Kids Institute, Subiaco, WA, Australia
- Peter C. Richmond
- 0Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia
- Peter C. Richmond
- 1Division of Pediatrics, School of Medicine, University of Western Australia, Perth Children’s Hospital, Perth, WA, Australia
- Anita H. J. van den Biggelaar
- 0Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia
- Beate Kampmann
- Vaccines & Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, Gambia
- Beate Kampmann
- 2Charité Centre for Global Health and Institute for International Health, Charité – Universitätsmedizin, Berlin, Germany
- William Pomat
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- Ofer Levy
- Precision Vaccines Program, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United States
- Ofer Levy
- Harvard Medical School, Boston, MA, United States
- Ofer Levy
- Broad Institute of Massachusetts Institute of Technology & Harvard, Cambridge, MA, United States
- Kinga K. Smolen
- Precision Vaccines Program, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United States
- Kinga K. Smolen
- Harvard Medical School, Boston, MA, United States
- DOI
- https://doi.org/10.3389/fimmu.2024.1425349
- Journal volume & issue
-
Vol. 15
Abstract
IntroductionDynamic cellular and molecular adaptations in early life significantly impact health and disease. Upon birth, newborns are immediately challenged by their environment, placing urgent demands on the infant immune system. Adenosine deaminases (ADAs) are enzymatic immune modulators present in two isoforms – ADA-1 and ADA-2. Infants exhibit low ADA activity, resulting in high plasma adenosine concentrations and a consequent anti-inflammatory/anti-Th1 bias. While longitudinal studies of plasma ADA have been conducted in infants in The Gambia (GAM), little is known regarding ADA trajectories in other parts of the world.MethodsHerein, we characterized plasma ADA activity in an infant cohort in Papua New Guinea (PNG; n=83) and compared to ontogeny of ADA activity in a larger cohort in GAM (n=646). Heparinized peripheral blood samples were collected at day of life (DOL) 0, DOL7, DOL30, and DOL128. Plasma ADA-1, ADA-2, and total ADA activities were measured by chromogenic assay.ResultsCompared to GAM infants, PNG infants had significantly lower ADA-1 (0.9-fold), ADA-2 (0.42-fold), and total ADA (0.84-fold) activities at birth which converged by DOL30.DiscussionOverall, discovery of a distinct baseline and a consistent pattern of increasing plasma ADA activity in early life in two genetically and geographically distinct populations validates and extends previous findings on the robustness of early life immune ontogeny.
Keywords
